COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
JAMA 10.1001/jama.2026.18191September 02, 2026 at 10:00 AM EDT
COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified.
MEDIA ADVISORY: 2026-27 Respiratory Virus Immunization Recommendations
Recommendations are informed by JAMA evidence reviews on influenza, COVID-19, and RSV.
An accompanying Perspective describes the background of the Vaccine Integrity Project, outlines the process for the 2026-2027 evidence review, and summarizes key findings regarding vaccine effectiveness and safety.
EMBARGOED PRESS BRIEFING: Tuesday, September 1
The Vaccine Integrity Project, the American Medical Association (AMA), and leading medical specialty societies will participate in an embargoed press briefing to outline the latest data on influenza, COVID-19 and RSV immunization, and to provide evidence-based recommendations for the upcoming 2026-27 respiratory virus season.
WHAT: Embargoed press briefing for 2026-2027 respiratory virus scientific evidence and immunization recommendations
WHEN: 1 P.M. EDT Tuesday, September 1
WHERE: The briefing will be via Zoom. Register online.
WHO:
Nicole Basta, PhD, MPhil, Vaccine Integrity Project Evidence Review Co-Lead
Christina Davidson, MD, American College of Obstetricians and Gynecologists (ACOG) Chief Medical Officer
Sandra Adamson Fryhofer, MD, AMA President-elect
Bruce Gelin, PhD, Vaccine Integrity Project Board of Advisors
Ronald G. Nahass, MD, MHCM, FIDSA, President of Infectious Diseases Society of America (IDSA)
Sarah C. Nosal, MD, FAAFP, American Academy of Family Physicians (AAFP) President
Andrew D. Racine, MD, PhD, American Academy of Pediatrics (AAP) President.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.